Neutralizing activity was also observed for antibodies against S2, but the potency was lower than of those against S1 27
Wang Y, Zhang M, Bi R, Su Y, Quan F, Lin Y, Yue C, Cui X, Zhao Q, Liu S, et al
In the Standards of Medical Care in Diabetes2021, the ADA recommend that for people with indications of high risk or established CKD either a sodium-glucose co-transporter-2 inhibitor (SGLT2i) or a glucagon-like peptide-1 receptor agonist (GLP-1 RA) be considered as a treatment option, independently of metformin use [15]
For most delivery system manufacturing processes, the correct answer is a combination: patent the aspects of the process that are independently important and that would be independently discovered by sophisticated competitors in any event, while maintaining as trade secrets the specific process conditions that are most commercially sensitive and least likely to be independently derived